[Aildenafil citrate: a new potent and highly selective phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction].
OBJECTIVE
To evaluate the efficacy and safety of aildenafil citrate, an oral phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction.


METHODS
Integrated analyses were made of 8-week, randomized, double-blind, placebo-controlled phase 2 clinical trials involving 250 men with mild-to-severe erectile dysfunction of various etiologies who received aildenafil citrate 30 or 60 mg (n = 167) or placebo (n = 83).


RESULTS
The statistic results of International Index of Erectile Function, Patient Sexual Encounter Profile (SEP) diaries and Global Assessment Question (GAQ) were significantly higher in the aildenafil citrate patients than in the placebo controls. The main drug-related adverse events were flushing, headache, dizziness and naupathia, which were mild and could be self-relieved.


CONCLUSIONS
The aildenafil citrate therapy significantly ameliorated erectile function and was well tolerated by a wide range of patients with erectile dysfunction.
He
Zhan-ju
ZJ
Department of Urology, First Hospital of Peking University, Institute of Urology, Peking University, Beijing 100034, China. hezhanju@263.net
Zhang
Kai
K
Jin
Jie
J
Li
Ning-chen
NC
Na
Yan-qun
YQ
Bai
Wen-jun
WJ
Wang
Xiao-feng
XF
Zhu
Ji-chuan
JC
Jiang
Hui
H
Yuan
Ren-pei
RP
Hong
Bao-fa
BF
Song
Tao
T
Yang
Yong
Y
Dai
Dong-xi
DX
D000284:Administration, Oral; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D013450:Sulfones / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D013450:Sulfones; C520604:aildenafil